

List of References Cited by Applicant

Atty Docket No.:	13783-105022		
Applicant (s):	Koenig et al.	Serial No.:	10/643,857
Filing Date:	August 14, 2003	Group Art Unit:	1644

U.S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass	Filing Date if appropriate
	A18	6,737,056	5/18/2004	Presta			
	A19	2004/0002587	1/1/2004	Watkins et al.			
	A20	2004/0185045 A1	9/23/2004	Koenig et al.			
	A21	2005/0037000 A1	2/17/2005	Stavenhagen et al.			
	A22	2005/0215767	9/29/2005	Koenig et al.			
	A23	2005/0260213 A1	11/24/2005	Koenig et al.			
	A24	2006/0013810	1/19/2006	Johnson et al.			
	A25	2006/0073142	4/6/2006	Chan et al.			
	A26	2006/0177439	8/10/2006	Koenig et al.			
	A27	2007/0253948	11/1/2007	Chan et al.			
	A28	11/754,015		Johnson et al.			5/25/2007
	A29	11/768,852		Johnson et al.			6/26/2007

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation Yes/No
	B10	WO 99/19362	04/22/1999	PCT			
	B11	WO 99/41285	08/19/1999	PCT			
	B12	EP 0 332 865	09/20/1989	EP			
	B13	EP 0 629 703	12/21/1994	EP			
	B14	EP 0 953 639	11/03/1999	EP			
	B15	WO 04/016750 A2	2/26/2004	PCT			
	B16	WO 05/110474 A2	11/24/2005	PCT			
	B17	WO 05/115452 A2	12/08/2005	PCT			

B18	WO 06/066078 A2	6/22/2006	PCT			
B19	PCT/US07/72151		PCT; filing date: June 26, 2007			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C79	Bewarder et al. In vivo and in vitro specificity of protein tyrosine kinases for immunoglobulin G receptor (FcγRIII) phosphorylation, Mol Cell Biol. 1996; 16(9):4735-43.
C80	Boruchov et al., Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. The Journal of Clinical Investigation 115; 10:2914-2923.
C81	Fleit et al., Cross-linking of mAb to FcγRIII results in tyrosine phosphorylation of multiple polypeptides including FcγRIII itself. Leukocyte Typing V: White cell differentiation antigens (Schlossman, Boumsell, Gilks, Harlan, Kishimoto, eds.) 1995; 826-827.
C82	Gamberale et al. To the editor: Expression of Fcγ receptors type II (FcγRII) in chronic lymphocytic leukemia B cells, Blood (Correspondence). 2003; 102(7):2698-2699.
C83	Kurlander et al. Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest. 1986; 77(6):2010-18.
C84	Looney et al. Human Monocytes and U937 cells bear two distinct Fc receptors for IgG. J Immunol. 1986; 136(5):1641-47.
C85	Maresco et al. The SH2-Containing 5'-inositol phosphate (SHIP) is tyrosine phosphorylated after Fcγ receptor clustering in monocytes. J Immunol. 1999; 162:6458-65.
C86	Ott et al. FcγRIII as a potential molecular target for intravenous gamma globulin therapy. J Allergy Clin Immunol. 2001; 108:S95-S98.
C87	Pardridge et al., Blood-brain barrier drug targeting: The future of brain drug development. Molecular Interventions. 2003; 3;2:90-105. See particularly pages 91-96.
C88	Pulford et al. The immunocytochemical distribution of CD16, CD32, and CD64 antigens. Leukocyte Typing V: White Cell Differentiation antigens (Schlossman, Boumsell, Gilks, Harlan, Kishimoto, eds.) 1995;817-821.
C89	Reff et al. A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Crit Rev Oncol Hematol. 2001; 40(1):25-35
C90	Schuna et al. New Drugs for the treatment of rheumatoid arthritis. Am J Health Syst Phar. 2000; 57:225-37.
C91	Su et al., Expression profile of FcγRIII on leukocytes and its dysregulation in systemic lupus erythematosus. J. Immunol. 178:3272-3280, 2007
C92	Van de Winkel et al. CD32 cluster workshop report. Leukocyte Typing V: White Cell Differentiation Antigens (Schlossman, Boumsell, Gilks, Harlan, Kishimoto, eds.) 1995;823-25.
C93	Vely et al. A new set of monoclonal antibodies against human Fc gamma RII (CD32) and Fc gamma RIII (CD16): characterization and use in various assays. Hybridoma. 1997; 16(6):519-28.
C94	Zola et al. CD32 (FcγRIII). J Biol Regul Homeost Agents. 2000; 14(4):311-16.

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.